Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dust mite extract mixture for perennial allergic rhinitis (phase II)
CTR20131419Phase 2Completed
- Sponsor
- Wolwo Biotech
- Start
- Feb 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of house dust mite allergen sublingual immunotherapy in allergic rhinitis (AR), sponsored by Wolwo Biotech. Started Feb 2015; status: completed.
02
Drugs
house dust mite allergen sublingual immunotherapy
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on CTR20131419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131419.